Phase 1B/2 study of the HSP90 inhibitor AUY922 plus trastuzumab in metastatic HER2-positive breast cancer patients who have progressed on trastuzumab-based regimen

This open-label, multicenter, phase 1B/2 trial assessed AUY922 plus trastuzumab in patients with locally advanced or metastatic HER2-positive breast cancer previously treated with chemotherapy and anti-HER2 therapy. This study was composed of a dose-escalation part with AUY922 administered weekly at...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Anthony, Rea, Daniel, Ahmed, Samreen, Beck, J. Thaddeus, López, Rafael López, Biganzoli, Laura, Armstrong, Anne C., Aglietta, Massimo, Alba, Emilio, Campone, Mario, Schmitz, Shu-Fang Hsu, Lefebvre, Caroline, Akimov, Mikhail, Lee, Soo-Chin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122341/
https://www.ncbi.nlm.nih.gov/pubmed/27129177
http://dx.doi.org/10.18632/oncotarget.8974

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122341/
https://www.ncbi.nlm.nih.gov/pubmed/27129177
http://dx.doi.org/10.18632/oncotarget.8974

Ejemplares similares